Sanofi gets Dupixent approved for the treatment of COPD in the EU

In the US, Sanofi expects a response by September 27.
Photo: Cole Burston/Reuters/Ritzau Scanpix
Photo: Cole Burston/Reuters/Ritzau Scanpix

Sanofi has received approval in Europe for the treatment of chronic obstructive pulmonary disease, COPD, with type 2 inflammation and chronic bronchitis, according to a stock exchange announcement.

Dupixent is already approved for the treatment of several conditions such as asthma and skin diseases, and last year alone sold for EUR 10.7bn, according to Bloomberg News. 

The US Food and Drug Administration is also reviewing an application for Dupixent for the treatment of COPD. Sanofi expects a response by September 27 at the latest. 

English edit: Catherine Brett

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Foto: Mike Blake/Reuters/Ritzau Scanpix

Gilead Sciences CMO to leave early 2025

For subscribers

Further reading